세계의 C형 간염 치료제 시장 : 질환 유형별, 약제 클래스별, 유통 채널별, 지역별 - 기회 및 예측(2018-2032년)

Global hepatitis C drugs market is projected to witness a CAGR of 3.72% during the forecast period 2025-2032, growing from USD 19.51 billion in 2024 to USD 26.14 billion in 2032. The hepatitis C drugs market is increasing steadily due to increasing infection rates, awareness of the disease, and increased use of direct-acting antiviral drugs that are associated with high cure rates and fewer side effects. Government programs, better diagnostics, and early screening programs have also improved the uptake of treatment in all parts of the world.

Growth drivers include increased access to healthcare in developing areas, affordable generic drugs and public health agencies continuing to support treatment options. Pharmaceutical partners, together with governments, public health agencies, and global awareness programs, will continue to accelerate efforts and goals aimed at eliminating Hepatitis C. Moreover, the arrival of personalised medicine, a growing capability of drug companies to provide treatment options tailored to individual patient needs, continues to drive innovation and treatment availability.

For instance, in March 2024, Teva UK Limited and Closed Loop Medicine Ltd announced a strategic partnership to develop personalised medicines by combining Teva's drugs with Closed Loop's digital dosing platform.

Rising Hepatitis C Cases Drive Market Growth

The rise in hepatitis C cases is the leading driver for the growth of the hepatitis C drug market. Hepatitis C will continue to be a problem due to unsafe clinical practices, contaminated blood transfusions and health care scarcity. In regions of the globe with limited access to healthcare, there is a limited ability to screen for hepatitis C. This leads to an increasing number of untreated, undiagnosed hepatitis C cases. Once people discover they have hepatitis C, they get tested and diagnosed. The development of all direct-acting antiviral drugs, which can cure hepatitis C in high percentages and with shorter durations, has disrupted the treatment paradigm for hepatitis C. In addition, pharmaceutical companies have opened access to therapies, including a variety of generic drugs and international collaborations, creating significantly more accessible treatment options. As the incidence of hepatitis C continues to rise, more cases are being diagnosed. In other healthcare and treatment settings, the hepatitis C drug market is expected to continue growing.

For instance, according to the data published in the Viral Hepatitis Surveillance Report - United States, 2023 by the Division of Viral Hepatitis, National Center for HIV, Viral Hepatitis, Sexually Transmitted Diseases, and Tuberculosis Prevention, Centers for Disease Control and Prevention, a total of 4,966 acute hepatitis C cases were reported by 47 states and the District of Columbia, corresponding to an estimated 69,000 acute infections. Additionally, 101,525 newly reported chronic hepatitis C cases were recorded by 45 states and the District of Columbia in 2023. There were 11,194 hepatitis C-related deaths reported.

Technological Innovations Drive Growth of the Global Hepatitis C Market

The hepatitis C drug market landscape is changing rapidly, primarily due to the introduction of advances in new technologies, which are making treatment easier, more effective, more accessible, and more tailored to patients' needs. At the heart of these advances are direct-acting antiviral therapies-simple, all-oral treatments, which can cure a person of the hepatitis C virus, with only mild side effects. In addition, genomic screening is an exciting new technology that allows doctors to determine which therapy a person is likely to respond to best by examining their genotype, as well as their treatment history for both the person and the virus. Public health programs are becoming increasingly important in taking an active approach to public health, through community testing, early diagnosis, and education about the virus. This approach is helping to eradicate the virus. Each of these advances takes us nearer to the goal of eliminating hepatitis C as a public health threat.

For instance, in March 2025, the UK Health Security Agency launched a whole genome sequencing service to strengthen efforts in tackling hepatitis C, marking another step toward England's continued progress in eliminating the virus as a public health threat.

For instance, in June 2025, AbbVie Inc. received expanded FDA approval for Mavyret (glecaprevir and pibrentasvir), making it the first approved treatment for acute hepatitis C virus infection. The approval allows earlier intervention in both adults and children aged three and older, with or without compensation for cirrhosis, improving access to timely care.

Combination Therapy Dominates Hepatitis C Drug Market Size

Combination therapy has quickly become the established segment in the hepatitis C drug market due to its ability to target the virus directly in multiple ways. By using different classes of antiviral agents, combination therapies target the virus in several physiological ways during several phases of the viral life cycle. Combination therapies have also been shown to have the capability of spellbinding single-drug treatments by providing more successful building blocks of therapy, reducing the risk of antiviral resistance, and subsequently reducing the treatment time from 12 months or longer to as short as 8 weeks. Additionally, clinicians typically demonstrate that combination regimens are very well tolerated and feasible for large categories of patients (including those with other co-morbid medical conditions). Combination therapy, through these means, has truly simplified treatment regimens, thereby minimizing the degree of patient disability from the disease and improving their life outcomes as appropriate. The simplification of treatment and improvement of patient outcomes have led to combination therapy being the predominant choice among other physicians and a primary driver of growth in the hepatitis C drug market.

In May 2025, Atea Pharmaceuticals, Inc. announced the results of a Phase 2 trial for an 8-week oral regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV), showing a 98% sustained virological response (SVR12) rate in treatment-adherent patients. The regimen was well tolerated, with a low risk of drug-drug interactions and no dose adjustments required for hepatic or renal impairment.

North America Dominates the Hepatitis C Drugs Market Size

North America is the world leader for hepatitis C drugs due to many factors, including high spending on healthcare, developed medical system capabilities, and a substantial population susceptible to the disease. The U.S. is facing a significant burden of hepatitis C due to large amounts of intravenous drug use, an aging population, and increasing rates of chronic liver disease. The region has early access to new direct-acting antiviral (DAA) drugs that have improved treatment outcomes with higher cure rates and fewer side effects compared to previous treatments. Furthermore, with a more developed regulatory environment in the U.S. and Canada, there is a more proactive reimbursement mechanism that supports most patients receiving therapeutic alternatives. The collaboration among pharmaceutical companies, research institutions, and governments has significantly advanced the treatment of hepatitis C and the development of hepatitis C drugs. These factors are compounded by the high investments made by North America into healthcare and public health initiatives that will help solidify the region as a leader in the hepatitis C drug market.

For instance, in November 2024, bioLytical Laboratories Inc. announced the availability of its INSTI HCV Antibody Test in Canada, following authorization by Health Canada. This rapid test enhances access to hepatitis C diagnosis, supporting ongoing efforts to improve treatment and disease management in the region.

Impact of U.S. Tariffs on the Global Hepatitis C Drugs Market

The U.S. tariffs on hepatitis C drugs could create widespread effects on both domestic and international markets. If tariffs are raised on imported pharmaceutical drugs or raw materials, the prices for treatment will likely increase, and may be unaffordable for patients, especially in low- and middle-income countries. Pharmaceutical companies may have increased operational costs which can lead to increased pricing or shortages of important pharmaceuticals due to disruptions in the global supply chain. This increased cost may divert resources away from research and development (R&D) on current R&D pipelines, further delaying important innovations for hepatitis C treatment. Generic drugs predominately made in countries such as India, may be exploited and exploited prices could in turn limit reducing price competition on access to treatment as generic drug production will be exceptionally exploited. Greater trade hostility may also fracture collaborative global health initiatives related to hepatitis C, negatively affecting international efforts to eradicate hepatitis C. Overall, U.S. tariffs on hepatitis C drugs could create barriers to progressing a more equitable access to life saving medicines especially from within resource poor settings.

Key Players Landscape and Outlook

The hepatitis C drug market is rapidly growing and transforming. Ongoing research in antiviral therapies and the introduction of personalized treatment strategies have permitted the market to expand rapidly. The market is transitioning towards safer, more targeted segments. Highly effective direct-acting antivirals (DAAs) are undergoing a fundamental shift in the treatment landscape, with a variety of new drugs designed to overcome issues with drug resistance and relapse rates. New combination therapies, including innovative classes of antivirals (such as protease inhibitors and polymerase inhibitors), will further raise cure rates and reduce treatment durations.

The increasing competitiveness amongst pharmaceutical companies has been driven by the need to fulfill the unmet clinical needs of patients suffering from chronic hepatitis C, specifically for treatment-naive patients, patients with advanced liver disease, and patients who have resistant strains of hepatitis C. Furthermore, regulatory agencies around the world are approving innovative therapies at a staggering pace, allowing many new drugs to enter the market at a rapid rate. Similarly, AbbVie, Inc.'s all-oral regimen, Mavyret, provides a simpler and more convenient option for patients, while also simplifying adherence. Merck & Co., Inc. also focuses on access to therapies and continually expanding access to treatments with Zepatier, particularly for underrepresented populations worldwide.

Big pharmaceutical companies are constantly innovating, working to develop shorter and more effective therapies while expanding access to established treatments. There is a significant investment of research and development funds aimed at developing the next best thing to conquer hepatitis C, while also providing a fair-priced product for both wealthy and resource-limited markets. These companies are committed to innovation while pursuing diverse access strategies. The outlook for the hepatitis C drug market is bright as the Key Player landscape continues to innovate.

For instance, in April 2025, AbbVie Inc., a global biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its updated hepatitis C treatment, Mavyret (glecaprevir/pibrentasvir), offering a shorter and more effective treatment regimen for hard-to-treat hepatitis C genotypes.

For instance, in April 2025, Gilead Sciences, Inc. announced that it would present its latest advancements in the treatment of Primary Biliary Cholangitis and Viral Hepatitis at an upcoming medical conference. These presentations will highlight new research and data on innovative therapies, showcasing the company's ongoing commitment to improving treatment outcomes for patients with liver diseases.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Hepatitis C Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Disease Type
    • 5.2.1.1. Acute Hepatitis C
    • 5.2.1.2. Chronic Hepatitis C
  • 5.2.2. By Drug Class
    • 5.2.2.1. HCV Protease Inhibitors
    • 5.2.2.2. HCV Polymerase Inhibitors
    • 5.2.2.3. HCV NSSA Inhibitors
    • 5.2.2.4. Combination Therapy
      • 5.2.2.4.1. Ledipasvir and Sofosbuvir
      • 5.2.2.4.2. Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir
      • 5.2.2.4.3. Elbasvir and Grazoprevir
      • 5.2.2.4.4. Others
    • 5.2.2.5. Interferon and Antiviral
    • 5.2.2.6. Peginterferon Alfa 2a
    • 5.2.2.7. Peginterferon Alfa 2b
    • 5.2.2.8. Ribavirin
    • 5.2.2.9. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Disease Type
  • 5.3.2. By Drug Class
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Hepatitis C Drugs Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Disease Type
    • 6.2.1.1. Acute Hepatitis C
    • 6.2.1.2. Chronic Hepatitis C
  • 6.2.2. By Drug Class
    • 6.2.2.1. HCV Protease Inhibitors
    • 6.2.2.2. HCV Polymerase Inhibitors
    • 6.2.2.3. HCV NSSA Inhibitors
    • 6.2.2.4. Combination Therapy
      • 6.2.2.4.1. Ledipasvir and Sofosbuvir
      • 6.2.2.4.2. Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir
      • 6.2.2.4.3. Elbasvir and Grazoprevir
      • 6.2.2.4.4. Others
    • 6.2.2.5. Interferon and Antiviral
    • 6.2.2.6. Peginterferon Alfa 2a
    • 6.2.2.7. Peginterferon Alfa 2b
    • 6.2.2.8. Ribavirin
    • 6.2.2.9. Others
  • 6.2.3. By Distribution Channel
    • 6.2.3.1. Hospital Pharmacies
    • 6.2.3.2. Retail Pharmacies
    • 6.2.3.3. Online Pharmacies
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Hepatitis C Drugs Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.1.1. Acute Hepatitis C
        • 6.3.1.2.1.2. Chronic Hepatitis C
      • 6.3.1.2.2. By Drug Class
        • 6.3.1.2.2.1. HCV Protease Inhibitors
        • 6.3.1.2.2.2. HCV Polymerase Inhibitors
        • 6.3.1.2.2.3. HCV NSSA Inhibitors
        • 6.3.1.2.2.4. Combination Therapy
        • 6.3.1.2.2.4.1. Ledipasvir and Sofosbuvir
        • 6.3.1.2.2.4.2. Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir
        • 6.3.1.2.2.4.3. Elbasvir and Grazoprevir
        • 6.3.1.2.2.4.4. Others
        • 6.3.1.2.2.5. Interferon and Antiviral
        • 6.3.1.2.2.6. Peginterferon Alfa 2a
        • 6.3.1.2.2.7. Peginterferon Alfa 2b
        • 6.3.1.2.2.8. Ribavirin
        • 6.3.1.2.2.9. Others
      • 6.3.1.2.3. By Distribution Channel
        • 6.3.1.2.3.1. Hospital Pharmacies
        • 6.3.1.2.3.2. Retail Pharmacies
        • 6.3.1.2.3.3. Online Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Hepatitis C Drugs Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Hepatitis C Drugs Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Hepatitis C Drugs Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Hepatitis C Drugs Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Regulatory Approvals
• 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Teva Pharmaceutical Industries Ltd.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. F. Hoffmann-La Roche Ltd
  • 21.3.3. GlaxoSmithKline plc
  • 21.3.4. Lupin Limited
  • 21.3.5. AbbVie Inc.
  • 21.3.6. Gilead Sciences, Inc.
  • 21.3.7. Bristol-Myers Squibb Company
  • 21.3.8. Janssen Pharmaceuticals, Inc.
  • 21.3.9. Merck & Co., Inc.
  • 21.3.10. Zydus Pharmaceuticals, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer